- Home
- RTO vs GMAB Comparison
RTO vs GMAB Comparison
Compare RTO & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RTO
- GMAB
- Stock Information
- Founded
- RTO 1925
- GMAB 1999
- Country
- RTO United Kingdom
- GMAB Denmark
- Employees
- RTO N/A
- GMAB N/A
- Industry
- RTO Business Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RTO Consumer Discretionary
- GMAB Health Care
- Exchange
- RTO Nasdaq
- GMAB Nasdaq
- Market Cap
- RTO 13.1B
- GMAB 15.0B
- IPO Year
- RTO N/A
- GMAB N/A
- Fundamental
- Price
- RTO $23.85
- GMAB $20.80
- Analyst Decision
- RTO Hold
- GMAB Buy
- Analyst Count
- RTO 2
- GMAB 8
- Target Price
- RTO $29.00
- GMAB $43.00
- AVG Volume (30 Days)
- RTO 585.0K
- GMAB 1.1M
- Earning Date
- RTO 01-28-2025
- GMAB 02-12-2025
- Dividend Yield
- RTO 2.42%
- GMAB N/A
- EPS Growth
- RTO 24.34
- GMAB 14.35
- EPS
- RTO 0.20
- GMAB 10.80
- Revenue
- RTO $6,837,109,965.00
- GMAB $2,967,926,227.00
- Revenue This Year
- RTO $4.06
- GMAB $32.03
- Revenue Next Year
- RTO $2.81
- GMAB $16.97
- P/E Ratio
- RTO $23.88
- GMAB $18.81
- Revenue Growth
- RTO 12.40
- GMAB 17.75
- 52 Week Low
- RTO $22.40
- GMAB $19.85
- 52 Week High
- RTO $34.07
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- RTO 39.23
- GMAB 45.42
- Support Level
- RTO $23.25
- GMAB $19.89
- Resistance Level
- RTO $23.95
- GMAB $21.26
- Average True Range (ATR)
- RTO 0.42
- GMAB 0.40
- MACD
- RTO -0.09
- GMAB -0.02
- Stochastic Oscillator
- RTO 25.64
- GMAB 38.16
About RTO Rentokil Initial plc
Rentokil Initial is the largest global provider of route-based pest-control and commercial hygiene services, operating in 83 countries. The group also offers a range of specialist route-based services including office and commercial space plant care, property care, and workwear rentals. The group has a diverse client base that includes global food producers, hotel chains, industrial goods businesses, restaurants, and individual residential customers.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.